AIVIS study with Korea University and Asan Medical Center validates AI's power in predicting colorectal cancer outcomes, advancing precision medicine. [PRIME ECONOMY] Medical Artificial Intelligence (AI) is opening new possibilities in pathology diagnostics and gaining attention on the international stage. AIVIS (CEO: Daehong Lee) announced on the 19th that its research on an AI model for predicting colorectal cancer prognosis has won the First Best Poster Prize at the European Congress of Pathology (ECP) 2025. This study was conducted jointly with a research team from Korea University Guro Hospital (Professor Jongwon Lee) and Asan Medical Center (Professor Seungmo Hong). The research revealed two key achievements: the AI model can predict the expression of a key prognostic biomarker (LRRC15) from standard H&E slides with 88% accuracy, potentially eliminating the need for expensive special stains. Furthermore, the same model can predict critical cancer staging information, including tumor invasion and lymph node status, with high accuracy. The ability to predict cancer stage using only H&E image analysis is evaluated as a major expansion of AI's potential to assist in the pathology diagnostic process in the future. Daehong Lee, CEO of AIVIS, stated, "This award is an achievement in which the clinical value of our AI technology, based on our pathology image analysis platform 'Qanti®Discovery,' has been globally recognized through collaboration with domestic researchers. From prognosis prediction to stage prediction, we will continue to set new standards in pathology diagnostics with AI and contribute to the advancement of precision medicine." Meanwhile, AIVIS has been selected for the 13th cohort of IBK Industrial Bank of Korea's startup accelerator program, 'IBK Changgong (Guro).' It is receiving support from the accelerator CNT Tech (CEO: Hwaseong Jeon).